News

Date Title View
Toggle Summary Aerie Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 2, 2017
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), (the "Company"), announced today that its first quarter 2017 financial results will be released after the market closes on Tuesday, May 2, 2017 . Following the release, the Company will host a live conference call and
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02%
Conference Call and Webcast Today, April 12 , at 5:00 p.m. ET IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Expansion of Commercialization Team
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointments
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
Conference Call and Webcast Today, March 7 , at 5:00 p.m. ET IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at Three Investor Conferences in March
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that company
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Resubmission of NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02%
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that on February
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2016 Financial Results and Host Conference Call on Tuesday, March 7, 2017
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), (the "Company"), announced today that its fourth quarter and year end 2016 financial results will be released after the market closes on Tuesday, March 7, 2017 . Following the release, the Company will host a live
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the RBC Capital Markets 2017 Global Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Casey
View HTML